Insmed | INSM - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Cytokinetics USD -206.03M 23M 2026-03
DBV Technologies USD -33.16M 8.6M 2025-09
Gilead Sciences USD 2.08B 1.56B 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -162.1M 164.84M 2026-03
Novartis USD 5.17B 637M 2025-09
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03